EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma
INCLUDING: any non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell lymphoma, transformed NHL histologies, etc.
\*Hodgkin's lymphoma
Life expectancy of 12 weeks or longer.
Subject must have received ≥ 1 prior treatment regimen.
The subject must not be a candidate for potentially curative therapy, including stem cell transplant.
You may not be if
Received an investigational study drug within 28 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug.
Received any approved anticancer medications within 21 days or 5 half-lives (whichever is longer) prior to receiving their first dose of study drug (42 days for nitrosoureas) EXCEPT steroids at ≤ 10 mg prednisone daily (or equivalent).
Has any unresolved toxicity ≥ Grade 2 from previous anticancer therapy.
Has history of brain metastases or spinal cord compression, or lymphoma involving the central nervous system.
Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3.
Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or is currently receiving immunosuppressive therapy following allogeneic transplant.
Received autologous hematopoietic stem cell transplant within the last 3 months.
Laboratory parameters not within the protocol-defined range.
Current or recent history (\<30 days prior to screening and/or \<45 days prior to dosing) of a clinically meaningful bacterial, fungal, parasitic or mycobacterial infection.
Current clinically active viral infection.
Known history of infection with the human immunodeficiency virus (HIV).
History of active hepatitis or positive serology for hepatitis.
